C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. Co.'s primary advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3 in clinical development for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable Bifunctional Degradation Activating Compounds degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors. The CCCC average annual return since 2020 is shown above.
The Average Annual Return on the CCCC average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CCCC average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CCCC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|